Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.
Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one da...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-08-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://doi.org/10.1371/journal.ppat.1009427 |
| _version_ | 1811173517772718080 |
|---|---|
| author | Pierre Bessière Marine Wasniewski Evelyne Picard-Meyer Alexandre Servat Thomas Figueroa Charlotte Foret-Lucas Amelia Coggon Sandrine Lesellier Frank Boué Nathan Cebron Blandine Gausserès Catherine Trumel Gilles Foucras Francisco J Salguero Elodie Monchatre-Leroy Romain Volmer |
| author_facet | Pierre Bessière Marine Wasniewski Evelyne Picard-Meyer Alexandre Servat Thomas Figueroa Charlotte Foret-Lucas Amelia Coggon Sandrine Lesellier Frank Boué Nathan Cebron Blandine Gausserès Catherine Trumel Gilles Foucras Francisco J Salguero Elodie Monchatre-Leroy Romain Volmer |
| author_sort | Pierre Bessière |
| collection | DOAJ |
| description | Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatment is beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. |
| first_indexed | 2024-04-10T17:48:20Z |
| format | Article |
| id | doaj.art-1d0652f69d9a41f9a08e502c8b431fb7 |
| institution | Directory Open Access Journal |
| issn | 1553-7366 1553-7374 |
| language | English |
| last_indexed | 2024-04-10T17:48:20Z |
| publishDate | 2021-08-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj.art-1d0652f69d9a41f9a08e502c8b431fb72023-02-02T22:56:58ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742021-08-01178e100942710.1371/journal.ppat.1009427Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.Pierre BessièreMarine WasniewskiEvelyne Picard-MeyerAlexandre ServatThomas FigueroaCharlotte Foret-LucasAmelia CoggonSandrine LesellierFrank BouéNathan CebronBlandine GausserèsCatherine TrumelGilles FoucrasFrancisco J SalgueroElodie Monchatre-LeroyRomain VolmerImpaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatment is beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease.https://doi.org/10.1371/journal.ppat.1009427 |
| spellingShingle | Pierre Bessière Marine Wasniewski Evelyne Picard-Meyer Alexandre Servat Thomas Figueroa Charlotte Foret-Lucas Amelia Coggon Sandrine Lesellier Frank Boué Nathan Cebron Blandine Gausserès Catherine Trumel Gilles Foucras Francisco J Salguero Elodie Monchatre-Leroy Romain Volmer Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathogens |
| title | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. |
| title_full | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. |
| title_fullStr | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. |
| title_full_unstemmed | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. |
| title_short | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. |
| title_sort | intranasal type i interferon treatment is beneficial only when administered before clinical signs onset in the sars cov 2 hamster model |
| url | https://doi.org/10.1371/journal.ppat.1009427 |
| work_keys_str_mv | AT pierrebessiere intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT marinewasniewski intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT evelynepicardmeyer intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT alexandreservat intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT thomasfigueroa intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT charlotteforetlucas intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT ameliacoggon intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT sandrinelesellier intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT frankboue intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT nathancebron intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT blandinegausseres intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT catherinetrumel intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT gillesfoucras intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT franciscojsalguero intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT elodiemonchatreleroy intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel AT romainvolmer intranasaltypeiinterferontreatmentisbeneficialonlywhenadministeredbeforeclinicalsignsonsetinthesarscov2hamstermodel |